(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr.

(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Behfar ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Mamta Parikh discussed ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Kidney Cancer Session II. Dr Mark Ball discussed ...

Across all aspects of daily life, artificial intelligence more than ever is harnessing the power of machine learning to automate and improve the efficiency of tasks. This is also true in medicine and, ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Session II. Dr. Trinity Bivalacqua ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3 rd – 6 th, 2024 was host to a prostate cancer session. Dr. Soroush Rais-Bahrami ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3 rd – 6 th, 2024 was host to a prostate cancer session. Dr. John Davis discussed the ...

(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a discussant presentation titled “Something Old, Something New, Something ...

Surgery remains the cornerstone of localized renal cell carcinoma (RCC) care. Pembrolizumab has recently been recommended as a standard of care for RCC patients who are at high risk of recurrence.

Aggressive variant prostate cancer (AVPC) is characterized by a molecular signature involving combined defects in TP53, RB1, and/or PTEN (AVPC-TSGs), identifiable through immunohistochemistry or ...